LEAF AI — CLINICAL INTELLIGENCE

Run tighter trials.
Deliver under budget.

AI-powered clinical trial management that eliminates the delays and cost overruns that haunt every CRO engagement — from site startup through TMF closeout.

Site Selection Study Startup Site Monitoring Data Management TMF Completeness Track Changes

Trials run over budget.
Not by accident.

The average Phase III trial runs 30% over budget and six months late. Behind every overspend is the same pattern: poor site selection, reactive monitoring, and a TMF left until the last minute.

~80%
of clinical trials fail to meet their enrollment timeline — the leading driver of study delays and budget overruns across all therapeutic areas.
$55,716
direct cost per day of a Phase III trial. Every month of delay adds over $1.5M in direct costs — before lost revenue is counted.
33–45%
of all GCP inspection findings across FDA and EMA are documentation-related — the single largest category of deficiency at both agencies.

Clinical intelligence, at every stage

Leaf AI scores potential sites against enrollment history, investigator experience, regulatory track record, and patient population density — before you commit a single dollar to startup.

Replace reactive site visits with continuous risk scoring. Leaf AI surfaces data anomalies, protocol deviations, and enrollment velocity issues the moment they emerge.

Real-time completeness tracking across all TMF zones. Every missing document, misclassified artifact, and metadata gap is flagged with remediation guidance — long before your inspection window.

leaf.ai / clinical / site-selection
SP
Which sites in our Phase II oncology study have the highest risk of slow enrollment based on historical data?
L

Site Enrollment Risk Analysis — ONCO-204

Analysed 14 active sites against 3-year enrollment history, screen failure rates, and current patient pipeline. Three sites require immediate attention:

Site 07 — Munich General
High Risk
Screen failure rate 48% (vs 22% protocol avg). Primary investigator on sabbatical Q2. Recommend contingency site activation. CTMS Data
Site 11 — Barcelona Clínic
Medium Risk
Enrollment tracking 1.8 patients/month vs 3.2 projected. IRB re-approval pending. Site coordinator turnover flagged. SIV Report
Sites 02, 05, 09 — On Track
On Target
CTMS · ONCO-204 Site Visit Reports IRB Tracker
leaf.ai / clinical / monitoring
SP
Summarise all outstanding protocol deviations and data queries that could impact our Q3 interim analysis.
L

Risk Summary — Q3 Interim Readiness

Across 14 sites, Leaf AI has identified 23 open protocol deviations and 147 outstanding data queries. Items material to the interim analysis:

6 Major deviations
17 Minor deviations
147 Open queries

Critical path item: Site 04 has 34 unresolved efficacy endpoint queries dating >21 days. At current resolution velocity, 11 will remain open at data cut. EDC · Medidata Recommend SDV escalation this week.

EDC · Medidata Rave CRA Visit Logs Protocol v3.1
leaf.ai / clinical / tmf-completeness
SP
What is our current TMF completeness score and which zones are at risk ahead of the MHRA inspection in 8 weeks?
L

TMF Completeness Report — ONCO-204

Overall TMF completeness: 74% against DIA Reference Model. At current completion velocity, projected completeness at inspection date is 81% — below the recommended 95% threshold.

Zone Complete Progress Status
01 — Trial Management 92%
On Track
04 — Site Management 61%
At Risk
07 — IP & Blinding 43%
Critical
08 — Safety Reporting 88%
On Track
eTMF · Veeva Vault DIA Reference Model MHRA Guidance 2024

From study startup to final TMF

01

Get ahead of the delay curve

Most trials are already behind before the sponsor realises it. Leaf AI is designed to be deployed fast — so you can surface risk signals, replan, and intervene while there is still time to change the outcome.

02

AI builds a live risk picture

Continuous analysis across enrollment velocity, site performance, protocol deviations, data quality, and TMF completeness. Every signal is scored, prioritised, and surfaced in real time.

03

Intervene before it costs you

Receive daily risk digests, intervention recommendations, and predictive cost impact estimates. Your team acts weeks earlier — before delays compound into budget overruns.

Everything your trial operations need

Leaf AI analyses your clinical programme the way your most experienced CRA would — systematically, continuously, and with complete visibility across every site. Talk to our team →

Intelligent site selection

Score candidate sites against enrollment history, investigator track record, regulatory compliance, and patient population data. Pick winners before SIV spend begins.

Continuous site monitoring

Replace periodic CRA visits with live risk scoring. Leaf AI flags data quality issues, protocol deviations, and enrollment anomalies the moment they appear in your EDC.

TMF completeness tracking

Real-time completeness scores against the DIA Reference Model. Every missing document, metadata gap, and misclassified artifact is flagged with owner-level remediation tasks — weeks before your inspection.

Study startup acceleration

Automate the coordination of site activation tasks — IRB submissions, contract execution, lab setup, and investigator training — with intelligent deadline tracking and blocker alerts.

Predictive budget modelling

Model the cost impact of emerging risks in real time. Translate site delays, query resolution rates, and enrollment shortfalls into projected budget variance before they crystallise.

Cross-system intelligence

Unify signals from your CTMS, EDC, eTMF, safety, and finance systems into a single intelligence layer. Ask anything about your trial in natural language and get an answer in seconds.

Clinical Intelligence FAQ

AI-powered clinical trial management uses machine learning to continuously analyse data from the CTMS, EDC, eTMF, and site systems — surfacing risks, predicting delays, and recommending interventions before small problems compound into costly overruns. Leaf AI replaces reactive, spreadsheet-driven oversight with live intelligence across every stage of your trial.

Leaf AI gives sponsors a real-time view of CRO performance across sites, data quality, TMF completeness, and budget trajectory — independently of what the CRO reports. Sponsors can identify emerging risks earlier, challenge scope changes with data, and avoid the information asymmetry that drives cost overruns in most CRO engagements.

Leaf AI continuously maps your eTMF content against the DIA Reference Model, scoring completeness by zone, section, and artifact type. It flags missing documents, metadata errors, misclassified files, and completeness velocity so you can course-correct weeks or months before an inspection — not in the final days when remediation is expensive and stressful.

No — Leaf AI amplifies your team. CRAs using Leaf AI spend less time on routine data review and more time on meaningful site intervention. Sponsors gain independent oversight without additional headcount. The result is the same team delivering better outcomes with fewer surprises and lower overall trial cost.

Stop absorbing the cost of avoidable delays

See how Leaf AI's Clinical Intelligence gives your team continuous, proactive oversight — from first site activation to final inspection.